16 results on '"Puzio-Kuter, Anna"'
Search Results
2. ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
- Author
-
Owczarek TB, Kobayashi T, Ramirez R, Rong L, Puzio-Kuter AM, Iyer G, Teo MY, Sánchez-Vega F, Wang J, Schultz N, Zheng T, Solit DB, Al-Ahmadie HA, and Abate-Shen C
- Subjects
- Adult, Aged, Aged, 80 and over, Animals, Cell Line, Tumor, Cisplatin therapeutic use, DNA Damage, Drug Resistance, Neoplasm, Female, Humans, Male, Mice, Mice, Inbred C57BL, Middle Aged, Neoplasm Invasiveness, Nuclear Proteins physiology, Tumor Suppressor Protein p14ARF analysis, Tumor Suppressor Protein p53 physiology, Urinary Bladder Neoplasms pathology, Xenograft Model Antitumor Assays, Tumor Suppressor Protein p14ARF physiology, Urinary Bladder Neoplasms drug therapy
- Abstract
Muscle-invasive bladder cancer (MIBC) generally responds poorly to treatment and tends to exhibit significant mortality. Here we show that expression of the tumor suppressor p14
ARF (ARF) is upregulated in aggressive subtypes of MIBC. Accumulation of ARF in the nucleolus is associated with poor outcome and attenuated response to chemotherapy. In both genetically engineered mouse models and murine xenograft models of human MIBC, we demonstrate that tumors expressing ARF failed to respond to treatment with the platinum-based chemotherapy agent cisplatin. Resistance was mediated in part by the integrin-binding protein ITGB3BP ( CENPR ) and reflected ARF-dependent impairment of protein translation, which was exaggerated by drug treatment. Overall, our results highlight a context-dependent role for ARF in modulating the drug response of bladder cancer. Cancer Res; 77(4); 1035-46. ©2017 AACR ., (©2017 American Association for Cancer Research.)- Published
- 2017
- Full Text
- View/download PDF
3. The Role of the p53 Protein in Stem-Cell Biology and Epigenetic Regulation.
- Author
-
Levine AJ, Puzio-Kuter AM, Chan CS, and Hainaut P
- Subjects
- Cell Division, DNA Replication, Humans, Mutation, Neoplasms genetics, Epigenesis, Genetic, Neoplasms physiopathology, Stem Cells cytology, Tumor Suppressor Protein p53 physiology
- Abstract
The p53 protein plays a passive and an active role in stem cells. The transcriptional activities of p53 for cell-cycle arrest and DNA repair are largely turned off in stem cells, but there is some indication that long-term stem-cell viability may require other p53-regulated functions. When p53 is activated in stem cells, it stops cell division and promotes the commitment to a differentiation pathway and the formation of progenitor cells. In the absence of any p53 activity, stem-cell replication continues and mistakes in the normal epigenetic pathway occur at a higher probability. In the presence of a functionally active p53 protein, epigenetic stability is enforced and stem-cell replication is regulated by commitment to differentiation. Over a lifetime of an organism, stem-cell clones compete in a tissue niche for Darwinian replicative advantages and in doing so accumulate mutations that permit stem-cell replication. Mutations in the p53 gene give stem cells this advantage, increase the clonal stem-cell population, and lower the age at which cancers can occur. Li-Fraumeni patients that inherit p53 mutations develop tumors in a tissue-type-specific fashion at younger ages. Throughout the life of a Li-Fraumeni patient, the tumor types that arise occur in tissues where stem cells are active and cell division is most rapid. Thus, p53 mutations that are inherited or occur during developmental life act in stem cells of the mesenchymal and epithelial lineages, whereas p53 mutations that occur in progenitor or differentiated (somatic) cells later in life function in tissues of endodermal origins, indicating that p53 may function differently in different developmental lineages., (Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
4. DTIE, a novel core promoter element that directs start site selection in TATA-less genes.
- Author
-
Marbach-Bar N, Bahat A, Ashkenazi S, Golan-Mashiach M, Haimov O, Wu SY, Chiang CM, Puzio-Kuter A, Hirshfield KM, Levine AJ, and Dikstein R
- Subjects
- Animals, Base Sequence, HEK293 Cells, Humans, MicroRNAs genetics, Sequence Homology, Nucleic Acid, Transcription, Genetic, Promoter Regions, Genetic, TATA Box genetics
- Abstract
The transcription start site (TSS) determines the length and composition of the 5' UTR and therefore can have a profound effect on translation. Yet, little is known about the mechanism underlying start site selection, particularly from promoters lacking conventional core elements such as TATA-box and Initiator. Here we report a novel mechanism of start site selection in the TATA- and Initiator-less promoter of miR-22, through a strictly localized downstream element termed DTIE and an upstream distal element. Changing the distance between them reduced promoter strength, altered TSS selection and diminished Pol II recruitment. Biochemical assays suggest that DTIE does not serve as a docking site for TFIID, the major core promoter-binding factor. TFIID is recruited to the promoter through DTIE but is dispensable for TSS selection. We determined DTIE consensus and found it to be remarkably prevalent, present at the same TSS downstream location in ≈20.8% of human promoters, the vast majority of which are TATA-less. Analysis of DTIE in the tumor suppressor p53 confirmed a similar function. Our findings reveal a novel mechanism of transcription initiation from TATA-less promoters., (© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.)
- Published
- 2016
- Full Text
- View/download PDF
5. Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells.
- Author
-
Tanne A, Muniz LR, Puzio-Kuter A, Leonova KI, Gudkov AV, Ting DT, Monasson R, Cocco S, Levine AJ, Bhardwaj N, and Greenbaum BD
- Subjects
- Animals, Humans, Immunity, Innate, Mice, Neoplasms immunology, Neoplasms genetics, RNA, Untranslated immunology
- Abstract
Recent studies have demonstrated abundant transcription of a set of noncoding RNAs (ncRNAs) preferentially within tumors as opposed to normal tissue. Using an approach from statistical physics, we quantify global transcriptome-wide motif use for the first time, to our knowledge, in human and murine ncRNAs, determining that most have motif use consistent with the coding genome. However, an outlier subset of tumor-associated ncRNAs, typically of recent evolutionary origin, has motif use that is often indicative of pathogen-associated RNA. For instance, we show that the tumor-associated human repeat human satellite repeat II (HSATII) is enriched in motifs containing CpG dinucleotides in AU-rich contexts that most of the human genome and human adapted viruses have evolved to avoid. We demonstrate that a key subset of these ncRNAs functions as immunostimulatory "self-agonists" and directly activates cells of the mononuclear phagocytic system to produce proinflammatory cytokines. These ncRNAs arise from endogenous repetitive elements that are normally silenced, yet are often very highly expressed in cancers. We propose that the innate response in tumors may partially originate from direct interaction of immunogenic ncRNAs expressed in cancer cells with innate pattern recognition receptors, and thereby assign a previously unidentified danger-associated function to a set of dark matter repetitive elements. These findings potentially reconcile several observations concerning the role of ncRNA expression in cancers and their relationship to the tumor microenvironment.
- Published
- 2015
- Full Text
- View/download PDF
6. The Evolution of Tumors in Mice and Humans with Germline p53 Mutations.
- Author
-
Levine AJ, Chan CS, Dudgeon C, Puzio-Kuter A, and Hainaut P
- Subjects
- Animals, Cyclin D genetics, Cyclin-Dependent Kinase 6 genetics, Gene Amplification, Gene Rearrangement, T-Lymphocyte, Genes, T-Cell Receptor, Heterozygote, Humans, Ikaros Transcription Factor genetics, Mice, Neoplasms genetics, PTEN Phosphohydrolase genetics, Germ-Line Mutation, Li-Fraumeni Syndrome genetics, Lymphoma genetics, Thymus Neoplasms genetics, Tumor Suppressor Protein p53 genetics
- Abstract
Mice with a homozygous p53 gene deletion develop thymic lymphomas by 9 wk of age. Using the sequence of the rearranged T-cell receptor gene from each clone of cells in the thymus, one can determine the number of independent transformation events. These tumors are oligoclonal, occurring at a frequency of 0.13-0.8 new cancer clones per day. By 20 wk only a few clones are detected, indicating competition among transformed cell clones. DNA sequencing of these tumors demonstrates a point mutation frequency of one per megabase and many genes that are consistently amplified or deleted in independent tumors. The tumors begin with an inherited p53 gene deletion. Next is a PTEN mutation in a stem cell or progenitor cell, before the rearrangement of the T-cell receptor. After that, the T-cell clone selects gene amplifications in cyclin D and cdk-6, and in Ikaros in the Notch pathway. Humans heterozygous for the p53 mutant gene in the germline (Li-Fraumeni syndrome) develop cancers at an early age. The penetrance of heterozygous p53 mutations is ∼93% of individuals developing tumors over their lives. At older ages the remaining 7% of this Li-Fraumeni population actually have a lower risk of developing tumors than the population at large with wild-type p53 genes., (Copyright © 2015 Cold Spring Harbor Laboratory Press; all rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
7. Whole-genome sequencing analysis of phenotypic heterogeneity and anticipation in Li-Fraumeni cancer predisposition syndrome.
- Author
-
Ariffin H, Hainaut P, Puzio-Kuter A, Choong SS, Chan AS, Tolkunov D, Rajagopal G, Kang W, Lim LL, Krishnan S, Chen KS, Achatz MI, Karsa M, Shamsani J, Levine AJ, and Chan CS
- Subjects
- Adult, Age of Onset, Animals, Child, Chromosome Segregation genetics, Comparative Genomic Hybridization, DNA Copy Number Variations genetics, Exome genetics, Family Characteristics, Female, Genome, Human genetics, Germ-Line Mutation genetics, Heterozygote, Humans, Male, Mice, Knockout, Middle Aged, Pedigree, Phenotype, Sequence Analysis, DNA, Tumor Suppressor Protein p53 genetics, Anticipation, Genetic, Genetic Heterogeneity, Genetic Predisposition to Disease, Li-Fraumeni Syndrome genetics, Neoplasms genetics
- Abstract
The Li-Fraumeni syndrome (LFS) and its variant form (LFL) is a familial predisposition to multiple forms of childhood, adolescent, and adult cancers associated with germ-line mutation in the TP53 tumor suppressor gene. Individual disparities in tumor patterns are compounded by acceleration of cancer onset with successive generations. It has been suggested that this apparent anticipation pattern may result from germ-line genomic instability in TP53 mutation carriers, causing increased DNA copy-number variations (CNVs) with successive generations. To address the genetic basis of phenotypic disparities of LFS/LFL, we performed whole-genome sequencing (WGS) of 13 subjects from two generations of an LFS kindred. Neither de novo CNV nor significant difference in total CNV was detected in relation with successive generations or with age at cancer onset. These observations were consistent with an experimental mouse model system showing that trp53 deficiency in the germ line of father or mother did not increase CNV occurrence in the offspring. On the other hand, individual records on 1,771 TP53 mutation carriers from 294 pedigrees were compiled to assess genetic anticipation patterns (International Agency for Research on Cancer TP53 database). No strictly defined anticipation pattern was observed. Rather, in multigeneration families, cancer onset was delayed in older compared with recent generations. These observations support an alternative model for apparent anticipation in which rare variants from noncarrier parents may attenuate constitutive resistance to tumorigenesis in the offspring of TP53 mutation carriers with late cancer onset.
- Published
- 2014
- Full Text
- View/download PDF
8. The interfaces between signal transduction pathways: IGF-1/mTor, p53 and the Parkinson Disease pathway.
- Author
-
Levine AJ, Harris CR, and Puzio-Kuter AM
- Subjects
- Animals, Humans, Mice, Parkinson Disease genetics, Signal Transduction, Insulin-Like Growth Factor I metabolism, Parkinson Disease metabolism, TOR Serine-Threonine Kinases metabolism, Tumor Suppressor Protein p53 metabolism
- Published
- 2012
- Full Text
- View/download PDF
9. The Role of p53 in Metabolic Regulation.
- Author
-
Puzio-Kuter AM
- Abstract
The metabolic changes that occur in a cancer cell have been studied for a few decades, but our appreciation of the complexity and importance of those changes is now being realized. The metabolic switch from oxidative phosphorylation to aerobic glycolysis provides intermediates for cell growth and division and is regulated by both oncogenes and tumor suppressor genes. The p53 tumor suppressor gene has long been shown to play key roles in responding to DNA damage, hypoxia, and oncogenic activation. However, now p53 has added the ability to mediate metabolic changes in cells through the regulation of energy metabolism and oxidative stress to its repertoire of activities. It is therefore the focus of this review to discuss the metabolic pathways regulated by p53 and their cooperation in controlling cancer cell metabolism.
- Published
- 2011
- Full Text
- View/download PDF
10. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes.
- Author
-
Levine AJ and Puzio-Kuter AM
- Subjects
- Adenosine Triphosphate metabolism, Cell Division, Citric Acid Cycle, Gene Expression Regulation, Neoplastic, Glucose metabolism, Glutamine metabolism, Glycolysis, Humans, NADP metabolism, Neoplasms drug therapy, Neoplasms pathology, Pentose Phosphate Pathway, Signal Transduction, Genes, Tumor Suppressor, Neoplasms genetics, Neoplasms metabolism, Oncogenes
- Abstract
Cells from some tumors use an altered metabolic pattern compared with that of normal differentiated adult cells in the body. Tumor cells take up much more glucose and mainly process it through aerobic glycolysis, producing large quantities of secreted lactate with a lower use of oxidative phosphorylation that would generate more adenosine triphosphate (ATP), water, and carbon dioxide. This is the Warburg effect, which provides substrates for cell growth and division and free energy (ATP) from enhanced glucose use. This metabolic switch places the emphasis on producing intermediates for cell growth and division, and it is regulated by both oncogenes and tumor suppressor genes in a number of key cancer-producing pathways. Blocking these metabolic pathways or restoring these altered pathways could lead to a new approach in cancer treatments.
- Published
- 2010
- Full Text
- View/download PDF
11. The origins and evolution of the p53 family of genes.
- Author
-
Belyi VA, Ak P, Markert E, Wang H, Hu W, Puzio-Kuter A, and Levine AJ
- Subjects
- Animals, Gene Expression Regulation physiology, Humans, Multigene Family, Protein Structure, Tertiary, Biological Evolution, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism
- Abstract
A common ancestor to the three p53 family members of human genes p53, p63, and p73 is first detected in the evolution of modern-day sea anemones, in which both structurally and functionally it acts to protect the germ line from genomic instabilities in response to stresses. This p63/p73 common ancestor gene is found in almost all invertebrates and first duplicates to produce a p53 gene and a p63/p73 ancestor in cartilaginous fish. Bony fish contain all three genes, p53, p63, and p73, and the functions of these three transcription factors diversify in the higher vertebrates. Thus, this gene family has preserved its structural features and functional activities for over one billion years of evolution.
- Published
- 2010
- Full Text
- View/download PDF
12. Mouse models of human bladder cancer as a tool for drug discovery.
- Author
-
Seager C, Puzio-Kuter AM, Cordon-Cardo C, McKiernan J, and Abate-Shen C
- Subjects
- Adenoviridae, Animals, Cell Line, Tumor, Female, Genetic Engineering methods, Genetic Vectors, Mice, Mice, Nude, Neoplasm Transplantation, Specimen Handling methods, Antineoplastic Agents pharmacology, Disease Models, Animal, Drug Discovery methods, Urinary Bladder Neoplasms drug therapy
- Abstract
Muscle-invasive bladder cancer is a deadly condition in dire need of effective new treatments. This unit contains a description of mouse models suitable for the evaluation of potential new therapies. Included is a genetically engineered mouse model of bladder cancer generated by the delivery of an adenovirus expressing Cre recombinase into the bladder lumen. Also described is an orthotopic mouse model created by the instillation of human bladder tumor cells into the bladder lumen of immune deficient mice. Protocols are also provided on the use of these models for the preclinical evaluation of new chemical entities, with mTOR inhibitors shown as an example.
- Published
- 2010
- Full Text
- View/download PDF
13. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.
- Author
-
Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, and Abate-Shen C
- Subjects
- Administration, Intravesical, Animals, Disease Progression, Female, Integrases metabolism, Intracellular Signaling Peptides and Proteins antagonists & inhibitors, Male, Mice, Mice, Knockout, PTEN Phosphohydrolase metabolism, Protein Serine-Threonine Kinases antagonists & inhibitors, TOR Serine-Threonine Kinases, Tumor Suppressor Protein p53 metabolism, Antibiotics, Antineoplastic administration & dosage, Disease Models, Animal, Sirolimus administration & dosage, Urinary Bladder Neoplasms prevention & control
- Abstract
Early-stage bladder cancer occurs as two distinct forms: namely, low-grade superficial disease and high-grade carcinoma in situ (CIS), which is the major precursor of muscle-invasive bladder cancer. Although the low-grade form is readily treatable, few, if any, effective treatments are currently available for preventing progression of nonmuscle-invasive CIS to invasive bladder cancer. Based on our previous findings that the mammalian target of Rapamycin (mTOR) signaling pathway is activated in muscle-invasive bladder cancer, but not superficial disease, we reasoned that suppression of this pathway might block cancer progression. To test this idea, we performed in vivo preclinical studies using a genetically engineered mouse model that we now show recapitulates progression from nonmuscle-invasive CIS to muscle-invasive bladder tumors. We find that delivery of Rapamycin, an mTOR inhibitor, subsequent to the occurrence of CIS effectively prevents progression to invasive bladder cancer. Furthermore, we show that intravesical delivery of Rapamycin directly into the bladder lumen is highly effective for suppressing bladder tumorigenesis. Thus, our findings show the potential therapeutic benefit of inhibiting mTOR signaling for treatment of patients at high risk of developing invasive bladder cancer. More broadly, our findings support a more widespread use of intravesical delivery of therapeutic agents for treatment of high-risk bladder cancer patients, and provide a mouse model for effective preclinical testing of potential novel agents.
- Published
- 2009
- Full Text
- View/download PDF
14. Stem cell biology meets p53.
- Author
-
Puzio-Kuter AM and Levine AJ
- Subjects
- Animals, Cell Differentiation physiology, Cells, Cultured, Fibroblasts cytology, Fibroblasts metabolism, Humans, Mice, Pluripotent Stem Cells cytology, Stem Cells cytology, Xenopus laevis, Pluripotent Stem Cells metabolism, Stem Cells metabolism, Tumor Suppressor Protein p53 metabolism
- Published
- 2009
- Full Text
- View/download PDF
15. Inactivation of p53 and Pten promotes invasive bladder cancer.
- Author
-
Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C, and Abate-Shen C
- Subjects
- Animals, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell metabolism, Humans, Lymphatic Metastasis, Male, Mice, Mice, Nude, Mice, Transgenic, Neoplasm Invasiveness, PTEN Phosphohydrolase genetics, Protein Kinases physiology, Rats, Signal Transduction, TOR Serine-Threonine Kinases, Tumor Suppressor Protein p53 genetics, Urinary Bladder Neoplasms genetics, Urinary Bladder Neoplasms metabolism, Carcinoma, Transitional Cell pathology, Cell Transformation, Neoplastic, Disease Models, Animal, PTEN Phosphohydrolase metabolism, Tumor Suppressor Protein p53 metabolism, Urinary Bladder Neoplasms pathology
- Abstract
Although bladder cancer represents a serious health problem worldwide, relevant mouse models for investigating disease progression or therapeutic targets have been lacking. We show that combined deletion of p53 and Pten in bladder epithelium leads to invasive cancer in a novel mouse model. Inactivation of p53 and PTEN promotes tumorigenesis in human bladder cells and is correlated with poor survival in human tumors. Furthermore, the synergistic effects of p53 and Pten deletion are mediated by deregulation of mammalian target of rapamycin (mTOR) signaling, consistent with the ability of rapamycin to block bladder tumorigenesis in preclinical studies. Our integrated analyses of mouse and human bladder cancer provide a rationale for investigating mTOR inhibition for treatment of patients with invasive disease.
- Published
- 2009
- Full Text
- View/download PDF
16. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model.
- Author
-
Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, and Abate-Shen C
- Subjects
- Animals, Antineoplastic Agents pharmacology, Disease Models, Animal, Dose-Response Relationship, Drug, Enzyme Inhibitors pharmacology, Hormones metabolism, Humans, MAP Kinase Signaling System, Male, Mice, Models, Biological, Prostatic Neoplasms pathology, TOR Serine-Threonine Kinases, Extracellular Signal-Regulated MAP Kinases metabolism, Prostatic Neoplasms metabolism, Protein Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism
- Abstract
The AKT/mammalian target of rapamycin (AKT/mTOR) and ERK MAPK signaling pathways have been shown to cooperate in prostate cancer progression and the transition to androgen-independent disease. We have now tested the effects of combinatorial inhibition of these pathways on prostate tumorigenicity by performing preclinical studies using a genetically engineered mouse model of prostate cancer. We report here that combination therapy using rapamycin, an inhibitor of mTOR, and PD0325901, an inhibitor of MAPK kinase 1 (MEK; the kinase directly upstream of ERK), inhibited cell growth in cultured prostate cancer cell lines and tumor growth particularly for androgen-independent prostate tumors in the mouse model. We further showed that such inhibition leads to inhibition of proliferation and upregulated expression of the apoptotic regulator Bcl-2-interacting mediator of cell death (Bim). Furthermore, analyses of human prostate cancer tissue microarrays demonstrated that AKT/mTOR and ERK MAPK signaling pathways are often coordinately deregulated during prostate cancer progression in humans. We therefore propose that combination therapy targeting AKT/mTOR and ERK MAPK signaling pathways may be an effective treatment for patients with advanced prostate cancer, in particular those with hormone-refractory disease.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.